The abstract is read at the publisher; the summary is JClub's.
In primary tumor-derived TAMs from glioblastoma multiforme patients, HDAC inhibitors enhanced phagocytosis and, with CD47 blockade, showed additive synergy, including pracinostat in xenografts.
- Why it matters: TAMs and microglia in GBM promote immune suppression, and while CD47-blocking antibodies can help, small-molecule ways to tune TAM phagocytosis and synergy are less explored.
- What they did: A patient-derived small-molecule screen tested 1,365 compounds on primary TAMs from GBM tumors, then validated HDAC inhibitors across multiple primary human TAM–GBM combinations and in a xenograft model.
- The result: Pracinostat suppressed tumor growth and extended survival in xenografts, with additive benefit plus CD47 antibodies; mechanistically, it induced NF-κB–linked transcriptional proinflammatory reprogramming and epigenetic priming of FcγR phagocytic machinery.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.